InvestorsHub Logo
Followers 88
Posts 5985
Boards Moderated 0
Alias Born 03/19/2007

Re: None

Sunday, 11/02/2014 3:37:55 AM

Sunday, November 02, 2014 3:37:55 AM

Post# of 97081
I for my part prefer to listen to the professionals in the world of financial newspapers as they have a excellent sensor about companies of "Tomorrow".

Forbes Headline:
J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit

http://www.forbes.com/sites/genemarcial/2013/03/11/jj-faces-potentially-disrupting-competition-in-its-lucrative-glucose-monitoring-business-from-tiny-diagnostics-outfit/

Taking the very "bullish" undertone of the Forbes article, when it was published, that since then DECN got 2 more victories versus J&J out of court.

And the conclusion from FORBES:

Decision Diagnostics could eventually gain a foothold in the high-margin market controlled by J&J and three other pharmaceutical giants. With Genstrip‘s approval, the product may attract other Big Pharma companies to either license it it or acquire all of Decision Diagnostics.